Seroprevalence and Risk Factors of Hepatitis Delta Virus in Chronic Hepatitis B Virus Infection in Zahedan

  • Alireza Bakhshipour Department of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
  • Mohammadali Mashhadi Department of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
  • Mahdi Mohammadi Health Promotion Research center, Zahedan University of Medical Sciences, Zahedan, Iran
  • Seyed Kazem Nezam Mail Department of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
Keywords:
Carrier, Cirrhosis, HBV, HDV, Iran, Prevalence

Abstract

Hepatitis delta virus (HDV) infection results in more severe and even fulminant form of hepatitis B in co-infected cases. This study was designed to estimate the prevalence of anti-HDV positivity and the associated risk factors in patients with chronic hepatitis B virus infection in Zahedan (Iran). In this cross-sectional study a total of 440 consecutive patients with chronic hepatitis B virus (HBV) infection attending the Zahedan Gastroenterology and Hepatology clinics from 2008 to 2011 were included. We performed test for HDV serum marker, using commercially available enzyme-linked immunosorbent assay kit. Patients were split into two groups according to their HDV antibody status as HDV positive or negative. The collected data were coded, and the statistical analyses were conducted. Four hundred and forty patients with various forms of chronic HBV-related liver diseases enrolled in the study. 200 (45.5%) patients were carrier for HBV. 196 (44.5%) patients had chronic active hepatitis and 44 (10%) patients suffered from cirrhosis. Anti-HDV was demonstrated in 75 patients (17%). The prevalence of HDV was 7%, 16.3% and 65.9% in carriers, patients with chronic active hepatitis and cirrhosis, respectively. HDV infection is still an important public health problem in Zahedan and appears a major cause of progression of liver disease induced by HBV.

References

Husa P, Linhartova A, Nemecek V, Husova L. Hepatitis D. Acta Virol. 2005;49(4):219-25.

Govindarajan S, Chin KP, Redeker AG, Peters RL. Fulminant B viral hepatitis: role of delta agent. Gastroenterology. 1984;86(6):1417-20.

Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C,Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003.

Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011Apr19.

Celen MK, Ayaz C, Hosoglu S, Geyik MF, Ulug M. Antihepatitis delta virus seroprevalence and risk factors in patients with hepatitis B in Southeast Turkey. Saudi Med J 2006; Vol. 27 (5): 617-620

Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Lankarani KB. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008;8(4):281-94.

Karimi A, Amini S, Amirkhani A. Investigation and Comparison of hepatitis D prevalence in dialysis patients and the donors of HBsAg carrier. Teb va Tazkieh. 2000;36:30-5. Persian.

Zahedi MJ. Serologic Prevalence of Hepatitis D in HBsAg positive patients in Kerman, South of Iran, 2002-2003. Kerman University of Medical Sciences and Health Services. Document No 81/55; 2003. Persian.

Foroutan H, Nemati A, Nasiri-Tosi M, Ghofrani H, Keivani H. Prevalence of hepatitis delta virus infection invarious groups with HBVinfection in Tehran, ImamKhomeini Hospital (2005-2006). Medical Journal of the Islamic Republic of Iran. 2008: 22(2):93-97.

Amini N, Alavian SM, Kabir A, Saiedi Hosseini SY, Aalaei-Andabili SH. Clinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta- Analysis. Hepat Mon. 2011; 11(12): 960-7.

Taghavi S, Sedighi S, Mehrabani D, Khademolhosseini F. Hepatitis D in chronic active hepatitis B: prevalence, liver enzymes and histopathology-an epidemiological study in Shiraz, southern Iran, 2003-2004. Hepat Mon. 2008;4(8):248-51.

Montazeri G, Rahban M, Mohamadnejad M, Zamani F, Hooshyar A, Fazlolahi A, Abedian S, Ghoujeghi F, Estakhri A, Montazeri F,Razjoyan H, Mamarabadi M, Alimohamadi M, Tavangar SM, Malekzadeh R. Liver histology and HBV DNA levels in chronically HBV infected patients with persistently normal alanineaminotransferase. Arch of Iranian Med, 2010; 13(3): 193-202.

Seifi SJ, Sabouri Ghannad M. A Study of HDV in HBsAg Positive Patients in Tabriz Northwestern Iran. Hepat Mon 2010; 10(2): 110-115.

Torabi S, Ebrahim-Poor S, Maljaie H, Naqili B. Seroepidemiologic study on hepatitis delta virus amongHBsAg positive subjects in Tabriz, Iran. Urmia Med J. 2002;13:290-7. Persian.

Hassanjani-Roshan MR, Taheri H. Frequency of Chronic Active Hepatitis in Asymptomatic HBV Carriers in Babol, Iran. Arch Iranian Med. 2002;5(2):90-100.

Ataei B, Yazdani MR, Kalantari H, Yaran M, Nokhodian Z, Javadi AA, Babak A, Adibi P. HDV infection in Isfahan, central Iran: Prevalence and risk factors among chronic HBV infection cases. Hepat Mon. 2011;11(4): 269-72.

Roshandel G, Semnani S, Abdolahi N, Besharat S, Keshtkar AA, Joshaqani H, Moradi A, Kalavi K, Jabbari A, Kabir MJ, Hosseini SA,Sedaqat SM, Danesh A,Roshandel D, Hedayat-Mofidi SM. Prevalence of hepatitis D virus infection in hepatitis B surface antigen-positive subjects in Golestan province, northeast Iran. J MicrobiolImmunol Infect. 2008;41(3):227- 30.

Mohammad Alizadeh AH, Ranjbar M, Tehrani AS, Keramat F, Mamani M, Rezazadeh M, Aini P, Khalilian A, Majlesi A, Hajilooi M. Seroprevalence of Hepatitis D Virus and its Risk Factors in the West of Iran. J Microbiol Immunol Infect 2010;43(6):519-523.

Hajiani E, Hashemi SJ, Jalali F. Seroprevalence of Delta Hepatitis in Patients with Chronic Hepatitis B and itsClinical Impact in Khuzestan Province, Southwest Iran. Hepat Mon. 2009;9(4): 287- 292.

Salehi M, Sanei-Moghaddam S, Khosravi S. Seroepidemiological study of HBVand HCV infection in the total population of Zahedan region, Iran. Tabib-EShargh2005;1;63-69. Persian

Sharifi-Mood B, Eshghi P, Sanei- Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J 2007;28:1516-9.

Genné D, Rossi I. Hepatitis delta in Switzerland: a silent epidemic. Swiss Med Wkly. 2011;141:w13176.

Sakugawa H, Nakasone H, Shokita H, Kawakami Y,Nakachi N, Adaniya H, Mizushima T, Nakayoshi T, Kinjo F, Saito A, Taira M, Takaesu H, Onga N. Seroepidemiological study on hepatitis delta virus infection in the Irabu Islands, Okinawa, Japan. J Gastroenterol Hepatol. 1997;12(4):299-304.

Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D, Radasan A, Micu G, Pertache I. A Cross- Sectional Epidemiological Study of HBV, HCV, HDV andHEV Prevalence in the SubCarpathian and South-Eastern Regions of Romania. J Gastrointestin Liver Dis 2010; 19 (1): 43-48.

Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, Shah HA, Jafri W. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol. 2005;20(10):1503-7.

Seetlani NK, Abbas Z, Raza S, Yakoob J, Jafri W. Prevalence of Hepatitis D in HBsAg positive patients visiting liver clinics. J Pak Med Assoc. 2009; 59:434- 437.

Sagnelli E, Stroffolini T, Ascione A, Chiaramonte M, Craxi A, Giusti G, et al. Decrease in HDV endemicity in Italy. J Hepatol 1997;26:20-4.

Gaete Gb, Stornaiuolo G, Precone DF. Type B and D viral hepatitis: epidiomological changes in Southern Europe. Forum (Genova). 2001;11(2):126-33.

How to Cite
1.
Bakhshipour A, Mashhadi M, Mohammadi M, Nezam SK. Seroprevalence and Risk Factors of Hepatitis Delta Virus in Chronic Hepatitis B Virus Infection in Zahedan. Acta Med Iran. 51(4):260-264.
QRcode
Section
Articles